Cite
HARVARD Citation
Weiss, J. et al. (2019). Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. Expert review of anticancer therapy. 19 (8), pp. 673-679. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Weiss, J. et al. (2019). Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer. Expert review of anticancer therapy. 19 (8), pp. 673-679. [Online].